Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$419.3m

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RCKT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 May 26SellUS$1,157John MilitelloIndividual384US$3.01
19 May 26SellUS$1,995Martin WilsonIndividual662US$3.01
19 May 26SellUS$7,261Gaurav ShahIndividual2,409US$3.01
13 May 26SellUS$3,083John MilitelloIndividual855US$3.61
13 May 26SellUS$9,837Gaurav ShahIndividual2,728US$3.61
13 May 26SellUS$12,120Martin WilsonIndividual3,361US$3.61
07 May 26SellUS$67,741Sarbani ChaudhuriIndividual17,650US$3.84
18 Feb 26SellUS$19,995Gaurav ShahIndividual5,990US$3.34
18 Feb 26SellUS$4,593Martin WilsonIndividual1,376US$3.34
18 Feb 26SellUS$3,862John MilitelloIndividual1,157US$3.34
13 Feb 26SellUS$12,341John MilitelloIndividual3,726US$3.31
13 Feb 26SellUS$40,668Gaurav ShahIndividual12,279US$3.31
13 Feb 26SellUS$40,582Martin WilsonIndividual12,253US$3.31
02 Jan 26BuyUS$34,400Elisabeth BjorkIndividual10,000US$3.44
18 Nov 25SellUS$18,721Gaurav ShahIndividual6,276US$2.98
18 Nov 25SellUS$3,240John MilitelloIndividual1,086US$2.98
18 Nov 25SellUS$7,592Jonathan SchwartzIndividual2,545US$2.98
18 Nov 25SellUS$4,910Martin WilsonIndividual1,646US$2.98
27 Aug 25BuyUS$34,100Elisabeth BjorkIndividual10,000US$3.41
19 Aug 25SellUS$4,839Martin WilsonIndividual1,592US$3.07
19 Aug 25SellUS$3,224John MilitelloIndividual1,060US$3.07
19 Aug 25SellUS$7,561Jonathan SchwartzIndividual2,485US$3.07
14 Aug 25SellUS$36,557Martin WilsonIndividual12,109US$3.02
14 Aug 25SellUS$21,263John MilitelloIndividual7,043US$3.02
14 Aug 25SellUS$33,695Jonathan SchwartzIndividual11,161US$3.02

Insider Trading Volume

Insider Buying: RCKT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RCKT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.0961%
Individual Insiders3,764,8843.45%
General Public7,395,3806.77%
Hedge Funds17,687,77216.2%
Institutions80,240,58673.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 73.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.2%
RTW Investments, LP
17,687,772US$67.9m0%0.56%
7.18%
BlackRock, Inc.
7,834,795US$30.1m-0.9%no data
4.68%
Citigroup Inc.
5,107,708US$19.6m-2.64%0.01%
4.3%
Vanguard Portfolio Management, LLC
4,690,215US$18.0m0%no data
4.11%
State Street Global Advisors, Inc.
4,485,989US$17.2m164%no data
3.46%
Vanguard Capital Management, LLC
3,775,736US$14.5m0%no data
3.27%
Maverick Capital, Ltd.
3,567,372US$13.7m42%0.13%
2.9%
Newtyn Management, LLC
3,165,900US$12.2m19.5%1.05%
2.86%
Millennium Management LLC
3,118,124US$12.0m74.7%0.01%
2.84%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
3,101,182US$11.9m1,890%no data
2.78%
Marshall Wace LLP
3,038,715US$11.7m11,400%0.01%
2.72%
AQR Capital Management, LLC
2,969,901US$11.4m345%no data
2%
Geode Capital Management, LLC
2,189,256US$8.4m3.25%no data
1.99%
D. E. Shaw & Co., L.P.
2,169,625US$8.3m-17.8%0.01%
1.89%
Monaco Asset Management S.A.M.
2,058,303US$7.9m-31.1%2.21%
1.34%
Gaurav Shah
1,467,962US$5.6m48.5%no data
1.22%
Eaton Vance Management
1,329,315US$5.1m32.6%no data
1.19%
UBS Asset Management AG
1,298,434US$5.0m757%no data
1.01%
Two Sigma Investments, LP
1,097,623US$4.2m-48.5%no data
0.99%
The Goldman Sachs Group, Inc.
1,078,087US$4.1m51.8%no data
0.94%
Federated Hermes, Inc.
1,023,747US$3.9m16.2%0.01%
0.93%
Point72 Asset Management, L.P.
1,012,126US$3.9m99.3%0.01%
0.87%
Opaleye Management Inc.
955,000US$3.7m0%0.35%
0.79%
T. Rowe Price Group, Inc.
859,874US$3.3m-9%no data
0.68%
JP Morgan Asset Management
738,007US$2.8m72.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 22:18
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity
Joshua SchimmerCantor Fitzgerald & Co.